Delineating the Molecular Spectrum and the Clinical, Imaging and Neuronal Phenotype of Chopra-Amiel-Gordon Syndrome
This study aims to understand Chopra-Amiel-Gordon Syndrome (CAGS), a rare genetic disease, by following patients over time to learn about their symptoms, brain changes on imaging, and learning challenges. Researchers will collect detailed information about how the condition affects individuals throughout their lives. This knowledge will help doctors better understand and potentially treat this genetic disorder.
Key Objective: The trial will establish a comprehensive understanding of CAGS's natural progression and clinical features to inform future treatment development and patient care strategies.
Who to Consider: Individuals with confirmed or suspected Chopra-Amiel-Gordon Syndrome should consider enrolling to contribute to scientific knowledge about this rare genetic condition.
Trial Parameters
Brief Summary
The purpose of this study is to establish the longitudinal natural history of individuals with confirmed or suspected Chopra-Amiel-Gordon Syndrome (CAGS) to learn more about the range of symptoms, changes in the structure of the brain seen on imaging, and learning difficulties that individuals with this disorder may experience. The investigators will obtain medical history, family history, MRI records, patient photographs, genetic test results, neurobehavioral and quality of life questionnaires from individuals with confirmed or suspected CAGS at annual research visits. Participants may also complete standardized research neurobehavioral assessments, research EEGs, and sample collections at each visit. This data will be maintained on a secure research database. Samples collected will be used for functional testing and the generation of iPSC cell lines, for neuronal reprogramming and phenotyping.
Eligibility Criteria
Inclusion Criteria: * Participants must have a variant in ANKRD17 with a classification of VUS, likely pathogenic, or pathogenic * Participants with a known diagnosis or CAGS have a disease-causing (likely pathogenic or pathogenic) variant in ANKRD17 evidenced by a pre-existing clinical genetic report. * Participants with a suspected diagnosis of CAGS must have a variant of uncertain significance in ANKRD17 evidenced by a pre-existing clinical genetic report and clinical features of CAGS * Participants with a VUS in ANKRD17 must have a variant of uncertain significance in ANKRD17 Exclusion Criteria: * No evidence of a disease-causing or potentially disease-causing variant ANRKD17 variant on a pre-existing clinical genetic report.